COMPARATIVE EFFICACY OF SODIUM–GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY IN ADULTS WITH HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
DOI:
https://doi.org/10.22159/ijcpr.2026v18i2.8085Keywords:
Heart failure, SGLT2 inhibitors, Cardiovascular mortality, Randomized controlled trials, Meta-analysisAbstract
Objective: To evaluate the effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors compared with placebo on cardiovascular mortality in adults with heart failure using evidence derived exclusively from randomized controlled trials.
Methods: A systematic review and meta-analysis of randomized controlled trials was conducted in accordance with PRISMA 2020 guidelines. Electronic databases were searched to identify eligible trials enrolling adult patients with heart failure that directly compared an SGLT2 inhibitor with placebo and reported cardiovascular mortality. Data were extracted from full-text publications, and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using an inverse-variance fixed-effect model. Statistical heterogeneity was assessed using Cochran’s Q test and the I² statistic.
Results: Four large, double-blind randomized controlled trials comprising 20,725 participants met the inclusion criteria. Across individual studies, SGLT2 inhibitor therapy was consistently associated with a lower risk of cardiovascular death compared with placebo. The pooled analysis demonstrated a statistically significant reduction in cardiovascular mortality with SGLT2 inhibitors (pooled RR = 0.88; 95% CI: 0.81–0.96). Statistical heterogeneity was negligible (I² = 0%), indicating high consistency across trials.
Conclusion: This meta-analysis demonstrates that SGLT2 inhibitors significantly reduce cardiovascular mortality in adults with heart failure. The consistency of benefit across heart-failure phenotypes and the low heterogeneity support the robustness of these findings and reinforce the role of SGLT2 inhibitors as a foundational component of contemporary heart-failure therapy.
Downloads
References
1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11. doi: 10.15420/cfr.2016:25:2, PMID 28785469.
2. Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421-34. doi: 10.1161/circresaha.121.318172, PMID 33983838.
3. Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):435-47. doi: 10.1016/j.jacc.2019.11.036, PMID 32000956.
4. Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-17. doi: 10.1007/s00125-018-4670-7, PMID 30132036.
5. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146(18):1383-405. doi: 10.1161/circulationaha.122.061732, PMID 36315602.
6. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368, PMID 34447992.
7. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editors. Cochrane handbook for systematic reviews of interventions. Version 6.4. London (UK): Cochrane; 2023. Available from: https://training.cochrane.org/handbook.
8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71, PMID 33782057.
9. McMurray JJ, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi: 10.1056/NEJMoa1911303, PMID 31535829.
10. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-24. doi: 10.1056/NEJMoa2022190, PMID 32865377.
11. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61. doi: 10.1056/NEJMoa2107038, PMID 34449189.
12. Solomon SD, McMurray JJ, Claggett B, De Boer RA, De Mets D, Hernandez AF. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-98. doi: 10.1056/NEJMoa2206286, PMID 36027570.
13. Sterne JAC, Higgins JPT, Elbers RG, Reeves BC. Risk of bias 2: a tool to assess risk of bias in randomised trials. Version 2.0. London (UK): Cochrane; 2019. Available from: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2.
14. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG outcome trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108-14. doi: 10.2337/dc16-0330, PMID 27289126.
15. Santos Gallego CG, Requena Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931-44. doi: 10.1016/j.jacc.2019.01.056, PMID: 30999996.
16. Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL. Cardiorenal syndrome: classification pathophysiology diagnosis and treatment strategies: a scientific statement from the American heart association. Circulation. 2019;139(16):e840-78. doi: 10.1161/CIR.0000000000000664, PMID 30852913.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Dr. Pranab Das, Dr. Mahaprasad Pal, Dr. Wasim Akram, Dr. Bodhisatya Das
This work is licensed under a Creative Commons Attribution 4.0 International License.